3,4-二羟基-6-[18F]氟-L-苯丙氨酸([18F]FDOPA) PET在疑似复发胶质瘤患者中的诊断价值已被认可。我们进行了一项多中心前瞻性研究，评估其在疑似高级别胶质瘤（HGG）复发患者的实际管理中的附加价值。经证实罹患WHO III和IV级别的HGG患者在接受初始标准护理治疗后，当MRI检查结果不能完全确定时，将被转介至多学科神经肿瘤委员会(MNOB)。每个案例进行了两个步骤的讨论。在第一步，仅基于临床和MRI数据进行诊断和管理建议。在第二步，重复同样的过程，考虑到[18F]FDOPA PET的结果。为每个步骤分配了决策的信心水平。测量[18F]FDOPA PET信息引起的诊断和管理变化。当未改变时，评估决策信心的差异。测量每个步骤的诊断表现。107名患者进行了共138次MNOB评估。建议的诊断在37例(26.8%)中从第一步到第二步发生了变化，建议的管理在31例(22.5%)中发生了变化。当管理没有变化时，MNOB最终决策的信心水平增加了87例(81.3%)。第一步的敏感性、特异性和准确性分别为83%、58%和66%，第二步分别为86%、64%和71%。[18F]FDOPA PET在HGG患者的随访中在临床实践中增加了重要信息。当MRI检查结果不明确时，它可以改变20%以上患者的管理并提高多学科委员会的决策信心水平。©2023年。作者(们)在Springer-Verlag GmbH Germany，Springer Nature的独家许可下。

Diagnostic value of 3,4-dihydroxy-6-[18F]fluoro-L-phenylalanine ([18F]FDOPA) PET in patients with suspected recurrent gliomas is recognised. We conducted a multicentre prospective study to assess its added value in the practical management of patients suspected of recurrence of high grade gliomas (HGG).Patients with a proven HGG (WHO grade III and IV) were referred to the multidisciplinary neuro-oncology board (MNOB) during their follow-up after initial standard of care treatment and when MRI findings were not fully conclusive. Each case was discussed in 2 steps. For step 1, a diagnosis and a management proposal were made only based on the clinical and the MRI data. For step 2, the same process was repeated taking the [18F]FDOPA PET results into consideration. A level of confidence for the decisions was assigned to each step. Changes in diagnosis and management induced by [18F]FDOPA PET information were measured. When unchanged, the difference in the confidence of the decisions were assessed. The diagnostic performances of each step were measured.107 patients underwent a total of 138 MNOB assessments. The proposed diagnosis changed between step 1 and step 2 in 37 cases (26.8%) and the proposed management changed in 31 cases (22.5%). When the management did not change, the confidence in the MNOB final decision was increased in 87 cases (81.3%). Step 1 had a sensitivity, specificity and accuracy of 83%, 58% and 66% and step 2, 86%, 64% and 71% respectively.[18F]FDOPA PET adds significant information for the follow-up of HGG patients in clinical practice. When MRI findings are not straightforward, it can change the management for more than 20% of the patients and increases the confidence level of the multidisciplinary board decisions.© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.